These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34101934)

  • 81. Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment.
    Giuliani J; Bonetti A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):505-508. PubMed ID: 31379219
    [No Abstract]   [Full Text] [Related]  

  • 82. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
    Lorusso V; Karthaus M; Aapro M
    Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy.
    Ito Y; Tsuda T; Minatogawa H; Kano S; Sakamaki K; Ando M; Tsugawa K; Kojima Y; Furuya N; Matsuzaki K; Fukuda M; Sugae S; Ohta I; Arioka H; Tokuda Y; Narui K; Tsuboya A; Suda T; Morita S; Boku N; Yamanaka T; Nakajima TE
    J Clin Oncol; 2018 Apr; 36(10):1000-1006. PubMed ID: 29443652
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.
    Keating GM
    Drugs; 2015 Dec; 75(18):2131-41. PubMed ID: 26613606
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
    Kitayama H; Tsuji Y; Sugiyama J; Doi A; Kondo T; Hirayama M
    Int J Clin Oncol; 2015 Dec; 20(6):1051-6. PubMed ID: 25822106
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Antiemetics: American Society of Clinical Oncology Focused Guideline Update.
    Hesketh PJ; Bohlke K; Lyman GH; Basch E; Chesney M; Clark-Snow RA; Danso MA; Jordan K; Somerfield MR; Kris MG;
    J Clin Oncol; 2016 Feb; 34(4):381-6. PubMed ID: 26527784
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
    Boccia R; Grunberg S; Franco-Gonzales E; Rubenstein E; Voisin D
    Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
    Roila F; Rolski J; Ramlau R; Dediu M; Russo MW; Bandekar RR; Grunberg SM
    Ann Oncol; 2009 Nov; 20(11):1867-73. PubMed ID: 19541792
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
    Navari RM; Gray SE; Kerr AC
    J Support Oncol; 2011; 9(5):188-95. PubMed ID: 22024310
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Park SH; Binder G; Corman S; Botteman M
    J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
    [No Abstract]   [Full Text] [Related]  

  • 92. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
    Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
    Kitazaki T; Fukuda Y; Fukahori S; Oyanagi K; Soda H; Nakamura Y; Kohno S
    Support Care Cancer; 2015 Jan; 23(1):185-90. PubMed ID: 25063271
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.
    Heron JF; Goedhals L; Jordaan JP; Cunningham J; Cedar E
    Ann Oncol; 1994 Sep; 5(7):579-4. PubMed ID: 7993831
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
    Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
    Darmani NA; Zhong W; Chebolu S; Mercadante F
    Pharmacol Biochem Behav; 2015 Apr; 131():104-11. PubMed ID: 25687374
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
    Aogi K; Sakai H; Yoshizawa H; Masuda N; Katakami N; Yanagita Y; Inoue K; Kuranami M; Mizutani M; Masuda N
    Support Care Cancer; 2012 Jul; 20(7):1507-14. PubMed ID: 21808994
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study).
    Radhakrishnan V; Venkatakrishnan K; Perumal Kalaiyarasi J; Selvarajan G; Mahaboobasha N; Victor PV; Anbazhagan M; Sivanandam DM; Rajaraman S
    JCO Glob Oncol; 2024 Jan; 10():e2300301. PubMed ID: 38237092
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
    Feinberg B; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
    Support Care Cancer; 2012 Mar; 20(3):615-23. PubMed ID: 21761096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.